Massachusetts General Hospital & Harvard Medical School
Shannon Stott, Ph.D., is an Assistant Professor in the Department of Medicine at Harvard Medical School and an Assistant in Genetics at the Massachusetts General Hospital Center for Cancer Research. Her laboratory is comprised of bioengineers, physicists and chemists focused on translating technological advances to relevant applications in clinical medicine. Specifically, Shannon is interested in using microfluidics and imaging technologies to create tools that increase understanding of cancer biology and of the metastatic process. In collaboration with the Toner, Haber and Maheswaran laboratories, Shannon has developed microfluidic devices that can isolate extraordinary rare circulating tumor cells (CTCs) from the blood of cancer patients. Her research also includes novel microfluidic devices for extracellular vesicle isolation and molecular characterization with a goal of earlier cancer detection.
Exploring the Biophysics of Circulating Tumor Cell Clusters Using Microfluidics
Advances in microfluidic technologies, biomaterials and molecular profiling have propelled the rapid growth and interest in achieving a ‘liquid biopsy’ in cancer. As malignant tumors grow, they will aggressively invade surrounding tissue due to rapidly dividing cancer cells that are nourished by an ample blood supply. As these cancer cells are multiplying, individual circulating tumor cells (CTCs) are released into the blood stream at very low numbers (1 in a billion), but are highly desirable due to their molecular cargo. In addition, thousands of tiny particles from the tumor will enter the blood stream, referred to as exosomes, which also contain genetic information about the tumor. Larger aggregates or clusters of tumor cells are thought to break off from the most aggressive cancers. Through a collaborative effort between bioengineers, biologists, and clinicians, my laboratory at Massachusetts General Hospital has developed microfluidic devices to isolate these rare circulating biomarkers from whole blood. Data from these devices will be presented with a focus on our recent effort to characterize the biophysics of clusters of CTCs and what the dynamics of their behavior might mean for understanding their role in metastasis.
Add to Calendar ▼2017-03-16 00:00:002017-03-17 00:00:00Europe/LondonBioEngineering 2017: BioMEMS, 3D-BioPrinting and Synthetic BiologyBioEngineering 2017: BioMEMS, 3D-BioPrinting and Synthetic Biology in Boston, USABoston, USASELECTBIOenquiries@selectbiosciences.com